SERVICE DETAIL
GENERATIVE AI &
COMPUTATIONAL DRUG DISCOVERY
The Algorithmic Mandate
Traditional drug discovery is an extraordinarily slow, linear process fraught with preclinical failures. The theoretical chemical space of potential drugs contains trillions of compounds.
By elevating pharmaceutical education into a computationally driven engineering discipline, KCCIRC utilizes Generative AI to navigate this hyper-dimensional space exponentially faster than physical screening.
Core Capabilities & Methodologies
De Novo Molecular Design
We engineer life-saving molecules from scratch using advanced artificial intelligence.
Generative Diffusion Models:
We leverage Generative Adversarial Networks (GANs) and Diffusion Models for the de novo design of small molecule inhibitors. We target historically intractable driver mutations (like mutant KRAS), mathematically optimizing for quantum-level binding affinities.
RNA Therapeutics:
We develop sophisticated generative architectures tuned specifically for the creation of programmable, targeted RNA-based therapeutics.
Structural Oncology & Biophysics
We chart the biophysical interactome at the atomic level to uncover cryptic vulnerabilities.
Foundation Models (AlphaFold):
We utilize state-of-the-art foundation models alongside microsecond-level molecular dynamics (MD) simulations to computationally map the folding pathways and conformational plasticity of master oncogenic regulators.
Thermodynamics of Binding:
We simulate the thermodynamics of targeted drug binding against complex kinase domains, computationally calculating the binding free energy to drastically accelerate lead optimization.
Computational Immunology & Synthetic Design
We utilize ultra-deep learning and structural predictions to build hyper-personalized, engineered cell therapies.
In-Silico Vaccines:
We utilize ultra-deep learning for the structural prediction of patient-specific neoantigen-MHC binding, laying the computational groundwork for hyper-personalized cancer vaccines.
Synthetic Promoters:
We computationally design synthetic regulatory circuits and customized promoters for CAR-T and NK cell therapies, maximizing efficacy while neutralizing systemic toxicity in hematological malignancies.
In-Silico Toxicology
Before a single physical compound is synthesized, our pipelines mathematically screen for global systemic safety.
Multi-Organ Interaction Mapping:
Before a single physical compound is synthesized, our in-silico toxicology pipelines simulate multi-organ interactions. This screens millions of compounds for off-target effects, predicting systemic toxicities and drastically reducing preclinical failure rates.
CLINICAL IMPACT
We are rewriting the rules of pharmacology by discovering entirely new allosteric binding networks on targets previously deemed "undruggable."
By predicting toxicity in the cloud rather than in the clinic, we are producing a pipeline of revolutionary precision medicines designed to flawlessly execute their algorithmic mandate: the permanent eradication of cancer.